IMFINZI is a registered trademark of the AstraZeneca group of companies. ©2018 AstraZeneca. All rights reserved. US-12936 7/18Severe infections. Signs and symptoms may include fever, cough, frequent urination,
pain when urinating, and fl u-like symptoms.
Severe infusion reactions. Signs and symptoms may include chills or shaking, itching
or rash, fl ushing, shortness of breath or wheezing, dizziness, fever, feeling like passing out,
back or neck pain, and facial swelling.
Getting medical treatment right away may help keep these problems from
becoming more serious. Your healthcare provider will check you for these problems
during your treatment with IMFINZI. Your healthcare provider may treat you with
corticosteroid or hormone replacement medicines. Your healthcare provider may delay or
completely stop treatment with IMFINZI if you have severe side effects.
Before you receive IMFINZI, tell your healthcare provider about all of your
medical conditions, including if you have immune system problems such as
Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant; have lung or
breathing problems; have liver problems; or are being treated for an infection.
If you are pregnant or plan to become pregnant, tell your healthcare provider. IMFINZI can
harm your unborn baby. If you are able to become pregnant, you should use an effective
method of birth control during your treatment and for at least 3 months after the last dose
of IMFINZI. Talk to your healthcare provider about which birth control methods to use. Tell
your healthcare provider right away if you become pregnant during treatment with IMFINZI.
If you are breastfeeding or plan to breastfeed, tell your healthcare provider. It is not known
if IMFINZI passes into breast milk. Do not breastfeed during treatment with IMFINZI and
for at least 3 months after the last dose of IMFINZI.
Tell your healthcare provider about all the medicines you take. This includes
prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of IMFINZI?
IMFINZI can cause serious side effects (see earlier).
The most common side effects in people with non-small cell lung cancer (NSCLC)
include cough, feeling tired, infl ammation in the lungs (pneumonitis), upper respiratory
tract infections, shortness of breath, and rash.
Tell your healthcare provider if you have any side effect that bothers you or that does
not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare
provider or pharmacist for more information.
Call your healthcare provider for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit http://www.FDA.gov/medwatch or call 1-800-FDA-1088.
Please see Brief Summary of complete Prescribing Information on the following
page.
If you cannot afford your medications, AstraZeneca may be able to help. Visit
AstraZeneca-us.com to fi nd out how.IMFINZI is an immunotherapy. People receiving IMFINZI had a 48% lower chance of lung cancer growing or
spreading than those receiving placebo (no medicine). It was also proven to give people 3x more time without
their cancer spreading compared with placebo.* Before IMFINZI, the last 10 years showed only limited
advancements to the current standard of care for unresectable Stage 3 NSCLC.
* In a clinical trial, the median time tumors did not grow or spread was 16.8 months for the 476 patients receiving IMFINZI compared with 5.6 months for
the 237 patients receiving placebo. Median is the middle number in a group of numbers arranged from lowest to highest. Individual results may vary.ASK YOUR DOCTOR ABOUT IMFINZI. VISIT IMFINZI.COM
FIRST & ONLY TREATMENT APPROVED
for people with unresectable Stage 3 non-small cell lung cancer (NSCLC)
whose disease has not progressed following concurrent
chemoradiation therapy (CRT).